238 related articles for article (PubMed ID: 27108405)
21. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo.
Schwarz EM; Campbell D; Totterman S; Boyd A; O'Keefe RJ; Looney RJ
J Orthop Res; 2003 Nov; 21(6):1049-55. PubMed ID: 14554218
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
23. Ceramic-on-ceramic THA associated with fewer dislocations and less muscle degeneration by preserving muscle progenitors.
Hernigou P; Roussignol X; Delambre J; Poignard A; Flouzat-Lachaniette CH
Clin Orthop Relat Res; 2015 Dec; 473(12):3762-9. PubMed ID: 26054482
[TBL] [Abstract][Full Text] [Related]
24. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
25. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
26. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study.
Arabmotlagh M; Rittmeister M; Hennigs T
J Orthop Res; 2006 Jul; 24(7):1336-41. PubMed ID: 16705719
[TBL] [Abstract][Full Text] [Related]
27. Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial.
Mahatma MM; Jayasuriya RL; Hughes D; Hoggard N; Buckley SC; Gordon A; Hamer AJ; Tomouk MW; Kerry RM; Eastell R; Wilkinson JM
Lancet Rheumatol; 2021 Mar; 3(3):e195-e203. PubMed ID: 38279382
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of the ABG-1 hydroxyapatite coated total hip arthroplasty: analysis of 111 cases with a minimum follow-up of 10 years.
Bidar R; Kouyoumdjian P; Munini E; Asencio G
Orthop Traumatol Surg Res; 2009 Dec; 95(8):579-87. PubMed ID: 19926546
[TBL] [Abstract][Full Text] [Related]
29. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
30. Wear and Osteolysis of Highly Crosslinked Polyethylene at 10 to 14 Years: The Effect of Femoral Head Size.
Lachiewicz PF; Soileau ES; Martell JM
Clin Orthop Relat Res; 2016 Feb; 474(2):365-71. PubMed ID: 25903943
[TBL] [Abstract][Full Text] [Related]
31. Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty.
Nakura N; Hirakawa K; Takayanagi S; Mihara M
J Bone Miner Metab; 2023 Mar; 41(2):239-247. PubMed ID: 36745212
[TBL] [Abstract][Full Text] [Related]
32. Risk analysis of patients with an osteolytic acetabular defect after total hip arthroplasty using subject-specific finite-element modelling.
Munro JT; Millar JS; Fernandez JW; Walker CG; Howie DW; Shim VB
Bone Joint J; 2018 Nov; 100-B(11):1455-1462. PubMed ID: 30418069
[TBL] [Abstract][Full Text] [Related]
33. Effect of Denosumab on Femoral Periprosthetic BMD and Early Femoral Stem Subsidence in Postmenopausal Women Undergoing Cementless Total Hip Arthroplasty.
Aro HT; Nazari-Farsani S; Vuopio M; Löyttyniemi E; Mattila K
JBMR Plus; 2019 Oct; 3(10):e10217. PubMed ID: 31687650
[TBL] [Abstract][Full Text] [Related]
34. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.
Ouyang Z; Zhai Z; Li H; Liu X; Qu X; Li X; Fan Q; Tang T; Qin A; Dai K
Biochem Pharmacol; 2014 Aug; 90(3):276-87. PubMed ID: 24950468
[TBL] [Abstract][Full Text] [Related]
35. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
36. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
[TBL] [Abstract][Full Text] [Related]
37. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Body JJ; Facon T; Coleman RE; Lipton A; Geurs F; Fan M; Holloway D; Peterson MC; Bekker PJ
Clin Cancer Res; 2006 Feb; 12(4):1221-8. PubMed ID: 16489077
[TBL] [Abstract][Full Text] [Related]
38. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
39. Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.
McClung MR; Zanchetta JR; Høiseth A; Kendler DL; Yuen CK; Brown JP; Stonkus S; Goemaere S; Recknor C; Woodson GC; Bolognese MA; Franek E; Brandi ML; Wang A; Libanati C
J Clin Densitom; 2013; 16(2):250-6. PubMed ID: 22572531
[TBL] [Abstract][Full Text] [Related]
40. Cementless cups do not increase osteolysis risk in metal-on-metal total hip arthroplasty. Apropos of 106 cases.
Beldame J; Carreras F; Oger P; Beaufils P
Orthop Traumatol Surg Res; 2009 Nov; 95(7):478-90. PubMed ID: 19801209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
